drugset / Trial / NCT01127646

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

NCT01127646

Phase 4 Terminated 23 enrolled Eli Lilly and Company
Non-randomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) of not taking the medication for a maximum of 6 days over a 28-day study treatment period.

Timeline

Start
2010-06
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 25 mg Oral
Subject Atomoxetine Other / unclassified 80 mg Oral
Comparator Methylphenidate Small molecule 18 mg Oral
Comparator Methylphenidate Small molecule 54 mg Oral